Possible drug-interaction between elexacaftor-tezacaftor-ivacaftor and repaglinide in an adult with cystic fibrosis-related diabetes

Can J Diabetes. 2024 Dec 26:S1499-2671(24)00413-1. doi: 10.1016/j.jcjd.2024.12.003. Online ahead of print.

¹ Division of Respirology, Department of Medicine, Nova Scotia Health. QEII - Halifax Infirmary, Suite 4449 Halifax Infirmary Building, 1796 Summer Street, Halifax, Nova Scotia, Canada, B3H 3A7. Electronic address: [email protected].
² Division of Respirology, Department of Medicine, Nova Scotia Health. QEII - Halifax Infirmary, Suite 4449 Halifax Infirmary Building, 1796 Summer Street, Halifax, Nova Scotia, Canada, B3H 3A7.
³ Division of Endocrinology & Metabolism, Department of Medicine, Nova Scotia Health. QEII - Victoria Building, Suite 7-North-046 Victoria Building, 1276 South Park Street, Halifax, Nova Scotia, Canada, B3H 2Y9.

No abstract available

Keywords: Cystic fibrosis; ETI; case report; drug interaction; liver toxicity; repaglinide.

Publication types